Insider Selling: Entellus Medical Inc (ENTL) Director Sells 101,319 Shares of Stock

Entellus Medical Inc (NASDAQ:ENTL) Director Brian E. Farley sold 101,319 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $23.85, for a total transaction of $2,416,458.15. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Brian E. Farley also recently made the following trade(s):

  • On Tuesday, October 3rd, Brian E. Farley sold 6,028 shares of Entellus Medical stock. The stock was sold at an average price of $19.17, for a total transaction of $115,556.76.
  • On Monday, October 2nd, Brian E. Farley sold 3,972 shares of Entellus Medical stock. The stock was sold at an average price of $19.10, for a total transaction of $75,865.20.

Entellus Medical Inc (NASDAQ ENTL) traded up $0.33 during midday trading on Friday, reaching $24.63. 388,451 shares of the company’s stock were exchanged, compared to its average volume of 722,815. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32. Entellus Medical Inc has a 1 year low of $11.47 and a 1 year high of $24.88.

Several institutional investors have recently modified their holdings of the company. Neuberger Berman Group LLC lifted its stake in shares of Entellus Medical by 152.2% in the third quarter. Neuberger Berman Group LLC now owns 58,000 shares of the medical technology company’s stock worth $1,071,000 after buying an additional 35,000 shares during the last quarter. Wells Fargo & Company MN increased its position in Entellus Medical by 74.7% during the third quarter. Wells Fargo & Company MN now owns 11,329 shares of the medical technology company’s stock worth $209,000 after acquiring an additional 4,846 shares during the period. Citadel Advisors LLC bought a new position in Entellus Medical during the third quarter worth $302,000. Archon Capital Management LLC increased its position in Entellus Medical by 14.9% during the third quarter. Archon Capital Management LLC now owns 550,224 shares of the medical technology company’s stock worth $10,157,000 after acquiring an additional 71,404 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Entellus Medical by 145.1% during the third quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock worth $168,000 after acquiring an additional 5,605 shares during the period. Institutional investors and hedge funds own 78.76% of the company’s stock.

Several analysts recently commented on ENTL shares. Piper Jaffray Companies restated a “buy” rating and set a $21.00 price target on shares of Entellus Medical in a report on Tuesday, August 22nd. BidaskClub upgraded shares of Entellus Medical from a “hold” rating to a “buy” rating in a research note on Saturday, August 19th. Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Monday, October 9th. TheStreet upgraded shares of Entellus Medical from a “d” rating to a “c-” rating in a research note on Thursday. Finally, ValuEngine upgraded shares of Entellus Medical from a “sell” rating to a “hold” rating in a research note on Thursday, December 7th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $20.40.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Entellus Medical Inc (ENTL) Director Sells 101,319 Shares of Stock” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/17/entellus-medical-inc-entl-director-brian-e-farley-sells-101319-shares-of-stock.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply